Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED  

Gold Index: 82941

You are here: home  > Pharmaceutical Chemicals API  > Antibiotic Drugs API  > Zidovudine CAS: 30516-87-1 Azidothymidine

Zidovudine CAS: 30516-87-1 Azidothymidine 

Payment Terms: T/T,L/C,WU 
Place of Origin: Zhejiang, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: C10H13N5O4
Production Capacity: 6 Kilogram/Year
Delivery Date: within 7 days
CAS No.: 30516-87-1
Molecular Formul: C10H13N5O4
Melting point: 106-112°C
Water solubility: 1-5 g/100 mL at 17°C
Means of Transport: Ocean,Land,Air
Packing: According to the request of...
Brand Name: MOSINTER
Brand: MOSINTER
CAS NO.: 30516-87-1
Molecular Weight: 267.2413
refractive index: 47 ° (C=1, H2O)

Zidovudine is a potent and selective inhibitor of HIV-1 replication.

Zidovudine CAS: 30516-87-1


Attribute


Molecular Formula:

C10H13N5O4

Molecular Weight:

267.2413

Melting point:

106-112°C

Water solubility

1-5 g/100 mL at 17°C

CAS Registry Number

30516-87-1

Water Solubility 

1-5 g/100 mL at 17 ºC


Zidovudine is a potent and selective inhibitor of HIV-1 replication.


Fire Hazard Flash point data for Zidovudine are not available; however, Zidovudine is probably combustible.

General Description: Slightly off-white odorless powdery solid.


Zidovudine (ZDV), also known as azidothymidine (AZT), is an antiretroviral medication used to prevent and treat HIV/AIDS.


It is of the nucleoside analog reverse-transcriptase inhibitor (NRTI) class. AZT inhibits the enzyme (reverse transcriptase) that HIV uses to synthesize DNA, thus preventing viral DNA from forming.


HIV prevention

AZT has been used as post-exposure prophylaxis (PEP) in combination with another antiretroviral, lamivudine, substantially reducing the risk of HIV infection following the first single exposure to the virus (such as a needle-stick injury involving blood or body fluids from an individual known or suspected of being infected with HIV) (though its use in PEP has largely been replaced by tenofovir as a component of a three drug combination).


AZT is now a principal part of the clinical pathway for both pre-exposure prophylaxis and post-exposure treatment of mother-to-child transmission of HIV during pregnancy, labor, and delivery and has been proven to be integral to uninfected siblings' perinatal and neonatal development. Without AZT, as many as 10 to 15% of fetuses with HIV-infected mothers will themselves become infected. AZT has been shown to reduce this risk to as little as 8% when given in a three-part regimen post-conception, delivery, and six weeks post-delivery. Consistent and proactive precautionary measures, such as the rigorous use of antiretroviral medications, cesarean section, face masks, heavy-duty rubber gloves, clinically segregated disposable diapers, and avoidance of mouth contact will further reduce child-attendant transmission of HIV to as little as 1–2%.


During the period from 1994 to 1999 when this was the primary form of prevention of mother-to-child HIV transmission, AZT prophylaxis prevented more than 1000 parental and infant deaths from AIDS in the United States. In the US at this time, the accepted standard of care for HIV-positive mothers was known as the 076 regimen and involved 5 daily doses of AZT from the second trimester onwards as well as AZT intravenously administered during labour. As this treatment was lengthy and expensive, it was deemed unfeasible in the global south, where mother-to-child transmission was a significant problem. A number of studies were initiated in the late 1990s that sought to test the efficacy of a shorter, simpler regimen for use in 'resource-poor' countries. This AZT short course was an inferior standard of care and would have been considered malpractice if trialed in the US; however it was nonetheless a treatment that would improve (at least to some extent) the care and survival of impoverished subjects, given local realities and the "shortages of staffing, medication and equipment that bound the possibilities of care" in such settings. The trials were highly controversial and highlighted the inability of researchers to align the local realities, such as the inaccessibility of the AZT, with the scientific and ethical protocols designed in 'resource-rich' countries.





Appearance: Fine powder

Packing: 25KG drum

bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: